VGN-R08b

Phase 1Small molecule

XXinhua Hospital, Shanghai Jiao Tong University School of Medicine

VGN-R08b is one of 5 small molecule programs targeting Gaucher Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gaucher DiseaseRecruiting

Gaucher DiseasePhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in Gaucher Disease

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Busulfex

ELELYSO

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

3 4

AZ-3102

AAzafaros A.G.

Phase 2

1 5

VGN-R08b

XXinhua Hospital, Shanghai Jiao Tong University School of Medicine

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1Recruiting

Gaucher Disease

NCT06272149

Clinical

Trials by Indication[1]

Gaucher Disease1 trial

An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease

Recruiting·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·Phase 1·NCT06272149·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VGN-R08b. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VGN-R08b compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VGN-R08b. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xinhua Hospital, Shanghai Jiao Tong University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: XXinhua Hospital, Shanghai Jiao Tong University School of Medicine

VGN-R08b

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Gaucher Disease1 trial

References

Drug Info

Quick Facts

Related News